NASDAQ:ACAD
ACADIA Pharmaceuticals Inc. Stock News
$17.05
-0.0300 (-0.176%)
At Close: May 03, 2024
FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
06:08pm, Wednesday, 29'th Jun 2022
Acadia won approval for its only commercialized drug Nuplazid in 2017 and has tried and failed to expand its label since. This month an FDA AdComm voted against an approval in Alzheimer's disease psyc
3 Big Ideas From Citigroup With Up to 80% Upside
12:38pm, Wednesday, 22'nd Jun 2022
As markets figure out a direction over the course of this summer, economic headwinds may be holding back some gains.
Why Acadia Pharmaceuticals Stock Is Crashing Today
04:07pm, Tuesday, 21'st Jun 2022 The Motley Fool
An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today?
02:58pm, Tuesday, 21'st Jun 2022
Today, investors in Acadia Pharmaceuticals and ACAD stock are in selling mode. The FDA gave a thumbs down on a key drug.
Why Acadia Pharmaceuticals Stock Is Crashing Today
12:07pm, Tuesday, 21'st Jun 2022
An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.
Biotech Stock Plummets After FDA Snub
10:30am, Tuesday, 21'st Jun 2022
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock is one of the worst stocks on the Nasdaq today, down 35.6% to trade at $12.56 at last check.
Why Acadia Pharma Shares Are Plunging Today
08:34am, Tuesday, 21'st Jun 2022
A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis.
FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid
03:27pm, Monday, 20'th Jun 2022 Zacks Investment Research
An FDA advisory committee votes against Acadia's (ACAD) Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis.
FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid
01:13pm, Monday, 20'th Jun 2022
An FDA advisory committee votes against Acadia's (ACAD) Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis.
Acadia Pharmaceuticals Inc. ACAD, +3.94% said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a t
HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate
03:46pm, Thursday, 16'th Jun 2022
HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected. It reiterates the stock with a Buy rating and a price target of $36.00.
Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA
02:42pm, Thursday, 16'th Jun 2022 Zacks Investment Research
The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.
Acadia (ACAD) Surges 15.5%: Is This an Indication of Further Gains?
12:41pm, Thursday, 16'th Jun 2022 Zacks Investment Research
Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA
12:20pm, Thursday, 16'th Jun 2022
The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.
Acadia (ACAD) Surges 15.5%: Is This an Indication of Further Gains?
10:50am, Thursday, 16'th Jun 2022
Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
